Semaglutide works as a glucagon-like peptide-1 (GLP-1) receptor agonist and is administered once weekly by injection. The effect is to reduce food intake by lowering appetite and slowing down digestion in the stomach, which helps to reduce body fat and weight.

Tirzepatide is an injectable medication originally developed for type 2 diabetes that is now also FDA-approved for chronic weight management in certain adults. It works by mimicking two natural hormones (GLP-1 and GIP) that regulate blood sugar, appetite, and metabolism. Tirzepatide slows digestion, helps regulate blood sugar, and decreases appetite, which together reduce overall calorie intake. Many patients also report improved control over cravings and portion sizes.

Most studies using Semaglutide evaluated patients after 68 weeks of ongoing weekly use and the average weight loss was 15-20% of body weight over that time period. Study participants also enjoyed greater improvement in cardiometabolic risk factors and an increase in participant-reported physical functioning from baseline. With Tirzepatide, results can vary, but clinical studies show patients may lose on average 15–20% of their body weight over 12–18 months when Tirzepatide is combined with lifestyle changes like healthy eating and physical activity. Individual results depend on factors such as starting weight, medical history, and adherence to treatment.